639 related articles for article (PubMed ID: 10791904)
1. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
2. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
[TBL] [Abstract][Full Text] [Related]
3. Difference between expression of adhesion molecules on CD34+ cells from bone marrow and G-CSF-stimulated peripheral blood.
Kröger N; Zeller W; Hassan HT; Dierlamm J; Zander AR
Stem Cells; 1998; 16(1):49-53. PubMed ID: 9474747
[TBL] [Abstract][Full Text] [Related]
4. CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow, and cord blood.
Sovalat H; Racadot E; Ojeda M; Lewandowski H; Chabouté V; Hénon P
J Hematother Stem Cell Res; 2003 Oct; 12(5):473-89. PubMed ID: 14594504
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
6. Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor.
Haas R; Möhle R; Murea S; Goldschmidt H; Pförsich M; Witt B; Hunstein W
J Hematother; 1994; 3(4):323-30. PubMed ID: 7537608
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients.
Fruehauf S; Schmitt K; Veldwijk MR; Topaly J; Benner A; Zeller WJ; Ho AD; Haas R
Br J Haematol; 1999 Jun; 105(3):786-94. PubMed ID: 10354148
[TBL] [Abstract][Full Text] [Related]
9. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
11. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
[TBL] [Abstract][Full Text] [Related]
12. Quantitative expression of adhesion molecules on granulocyte colony-stimulating factor-mobilized peripheral blood, bone marrow, and cord blood CD34+ cells.
Gigant C; Latger-Cannard V; Bensoussan D; Feugier P; Bordigoni P; Stoltz JF
J Hematother Stem Cell Res; 2001 Dec; 10(6):807-14. PubMed ID: 11798507
[TBL] [Abstract][Full Text] [Related]
13. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
Gazitt Y; Akay C; Thomas C
Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
[TBL] [Abstract][Full Text] [Related]
14. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
[TBL] [Abstract][Full Text] [Related]
15. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
[TBL] [Abstract][Full Text] [Related]
18. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
19. Expression of differentiation antigens and adhesion molecules on CD34+ cells in peripheral blood and bone marrow after chemotherapy followed by administration of granulocyte colony stimulating factor.
Masauzi N
Hokkaido Igaku Zasshi; 1996 Nov; 71(6):771-83. PubMed ID: 8996844
[TBL] [Abstract][Full Text] [Related]
20. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF.
Bellucci R; De Propris MS; Buccisano F; Lisci A; Leone G; Tabilio A; de Fabritiis P
Bone Marrow Transplant; 1999 Jan; 23(1):1-8. PubMed ID: 10037043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
